What is Genmab?
Genmab is a biotechnology company company serving enterprise, commercial, consumer, healthcare, financial, real estate, or regulated-market customers.
- Category
- Biotechnology company
- Headquarters
- Copenhagen, Denmark
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; Nasdaq Copenhagen/Nasdaq: GMAB
What is Genmab?
Genmab is a biotechnology company company headquartered in Copenhagen, Denmark. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Genmab is a biotechnology company company headquartered in Copenhagen, Denmark. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Genmab should be mapped as a scaled public-company account. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Genmab offer?
Genmab's profile centers on Antibody therapeutics, Oncology, Clinical development, Partnered medicines.
- Antibody therapeutics· Biotechnology company
- Oncology· Biotechnology company
- Clinical development· Biotechnology company
- Partnered medicines· Biotechnology company
- Research platforms· Biotechnology company
- Commercialization· Biotechnology company
How does Genmab make money?
Genmab makes money through commercial activity tied to biotechnology company.
Genmab monetizes through the model common to biotechnology company: product sales, recurring services, contracts, leases, subscriptions, transaction volume, servicing, investment management, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, occupancy, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Genmab?
Genmab's named executives should be verified on the official leadership or investor-relations page before outreach.
- Genmab executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Genmab finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Genmab operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Genmab's leadership?
Genmab should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.genmab.comHow is Genmab funded?
Genmab's current status is Public company; Nasdaq Copenhagen/Nasdaq: GMAB.
Genmab's capital profile is best understood through its current public-company status: Public company; Nasdaq Copenhagen/Nasdaq: GMAB. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Genmab get here?
Genmab's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingGenmab is foundedThe company begins building in biotechnology company.
- Scale-upCommercial footprint expandsGenmab broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; Nasdaq Copenhagen/Nasdaq: GMABPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Genmab's competitors?
Genmab competes with larger incumbents and focused specialists in biotechnology company.
Genmab — frequently asked questions
